Engineering Microorganisms as Precision Factories and Functional Solutions. Microbial genetic engineering is the foundational pillar of synthetic biology, enabling the redesign of bacteria, fungi, and yeast to perform novel biological functions. CD Biosynsis provides a comprehensive Microbial Genetic Engineering Service, offering a versatile toolbox of cutting-edge technologies—from CRISPR-Cas9 precision editing to large-scale metabolic pathway reconstruction. By re-wiring the genetic circuitry of microorganisms, we empower researchers to transform simple microbial hosts into efficient bio-factories, specialized therapeutic delivery vehicles, and resilient agricultural enhancers.
Get a Technical QuoteOur microbial platform supports a vast array of species including E. coli, B. subtilis, S. cerevisiae, and unconventional industrial or environmental strains. We bridge the gap between digital genetic design and large-scale functional reality.
| Service Tier | Technical Focus | Primary Application | Industrial/Research Value |
|---|---|---|---|
| Custom Strain Construction | Gene KO/KI & Point mutations | Basic research & Target validation | Tailored genotypes for pathway study |
| Metabolic Engineering | Heterologous gene expression | Bio-manufacturing & Nutraceuticals | Redirects carbon flux to targets |
| Genome-Scale Rewiring | Large-scale genomic editing | Industrial strain optimization | Enhances robustness and fermentation yield |
| Synthetic Circuit Design | Inducible & Feedback systems | Precision biosensing & Therapeutics | Enables smart environmental responses |
| Microbiome Modification | Community-targeted editing | Soil health & Gut microbiome | Optimizes multi-species symbiosis |
1. Chassis Design
2. Tool Synthesis
3. Transformation
4. Yield Validation
Identifying the optimal host and using bioinformatic tools to design synthetic pathways or genomic modifications.
Project feasibility study and Mutual NDA signing.
Designing and synthesizing gRNAs, donor DNA, and expression vectors optimized for specific microbial codon bias.
Customizing vectors for high-copy or stable genomic integration.
Executing genetic modification via high-efficiency transformation, electroporation, or conjugation systems.
Careful selection of clones to ensure the absence of unwanted mutations.
Assessing performance through lab-scale fermentation, metabolite profiling, and stress-response assays.
Final delivery of engineered strains and comprehensive characterization dossiers.
We benchmark our engineering efficiency against landmark metabolic and genomic research.
Microbial hosts can be transformed into producers of high-value plant metabolites. Benchmarks have demonstrated the reconstruction of the resveratrol pathway in E. coli. By introducing plant-derived enzymes (STS gene) and optimizing precursor supply, researchers achieved efficient biosynthesis, showcasing the potential for sustainable therapeutic production.
(Reference: Biosynthesis of Resveratrol in E. coli, 2021)
The pharmaceutical industry relies on engineered microbes for novel agents. Utilizing CRISPR-Cas9, researchers have successfully knocked out metabolic inhibitors and overexpressed key enzymes to create production strains for new antimicrobial peptides and anti-cancer compounds, proving direct value in drug discovery.
(Reference: Engineering Microbes for Pharmaceuticals, 2025)
Research has focused on modifying rhizobia and B. subtilis to enhance nitrogen fixation and express pest-resistant proteins. By introducing heterologous genes and knocking out negative regulators, engineered microbes better promote plant growth and resist environmental stressors, offering alternatives to chemical fertilizers.
(Reference: Engineered Microbes in Sustainable Agriculture, 2020/2025)
Bridging the gap to industrial scale is essential. Strategies involving yeast engineering have focused on knocking out byproduct pathways to maximize synthesis of vitamins and amino acids. Combining genetic refinements with bioprocess optimization has significantly enhanced yield and economic feasibility for global impact.
(Reference: Scaling Up Microbial Nutraceuticals, 2024)
Ready to transform your microbial host into a precision bio-factory?
Contact Us1. Can you edit non-model or environmental microorganisms?
Yes. While E. coli and yeast are standard, we have extensive experience developing genetic tools for diverse strains, including actinomycetes, bacilli, and various industrial fungi.
2. What is the typical turnaround time for a custom strain?
Depending on the complexity, standard knockout projects usually take 4-8 weeks, while complex metabolic pathway engineering may take 12 weeks or more.
3. How do you ensure the stability of the engineered genes?
We offer various strategies including genomic integration at safe harbor loci to prevent plasmid loss and the use of antibiotic-free selection systems for large-scale production.
4. Do you offer metabolic flux analysis for engineered strains?
Absolutely. We provide comprehensive metabolite profiling and flux analysis to help identify bottlenecks and further optimize production yields.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.